Emma Walmsley, the first female CEO of a major pharmaceutical company, will step down as GSK’s leader at the end of 2025. Her successor, Luke Miels, currently GSK’s chief commercial officer, will take over January 1. Walmsley guided GSK through a strategic pivot focusing on specialty medicines and vaccines, expanding oncology and HIV portfolios while spinning off consumer health. Despite challenges including missed COVID-19 vaccine opportunities, GSK forecasts significant revenue growth driven by upcoming drug launches. The leadership change marks a pivotal moment for the company’s next phase.